A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
HiFiBiO Therapeutics
HiFiBiO Therapeutics
Eastern Cooperative Oncology Group
Dana-Farber Cancer Institute
Northwestern University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Duke University